Opiant Pharmaceuticals Inc (OPNT)

Overview

Opiant Pharmaceuticals, Inc. is a specialized pharmaceutical company dedicated to the development of innovative treatments aimed at addressing various types of addictions and drug overdoses. With a strong emphasis on combating the opioid crisis, Opiant has made notable strides since its inception in 2005 when it was originally known as Lightlake Therapeutics Inc. The company rebranded to its current name in January 2016, reflecting its commitment to the fight against addiction. Opiant’s corporate headquarters are situated in Santa Monica, California, serving as the hub for its research and development efforts.

The firm is primarily recognized for its groundbreaking product, the NARCAN nasal spray, which plays a crucial role in reversing opioid overdoses. Beyond this key offering, Opiant is actively advancing a diverse development pipeline that includes several promising drug candidates targeting opioid overdose, as well as alcohol use disorders, acute cannabinoid overdose, and broader opioid use disorders. This multifaceted approach positions Opiant as a critical player in the pharmaceutical landscape aimed at improving public health outcomes related to substance use disorders.

Products and Services

• NARCAN Nasal Spray

  A life-saving medication designed to rapidly reverse opioid overdoses, NARCAN offers a user-friendly, needle-free delivery system that can be administered by bystanders, first responders, or even individuals at risk of overdose. Its efficacy has made it a pivotal tool in combating the devastating impacts of the opioid crisis.

• Opioid Overdose Reversal Candidates

  In addition to NARCAN, Opiant is developing novel therapeutic agents specifically aimed at reversing opioid overdoses. These candidates are designed to enhance recovery outcomes and provide additional options in acute overdose situations.

• Alcohol Use Disorder Treatments

  Opiant's pipeline includes several innovative drug candidates intended for the treatment of alcohol use disorders. These therapies aim to help individuals struggling with alcohol dependence achieve better management of their condition and support their recovery journey.

• Acute Cannabinoid Overdose Solutions

  In response to the increasing acknowledgment of cannabinoid overdoses, Opiant is also committed to developing solutions tailored for acute cannabinoid overdoses. These products aim to offer safe and effective interventions for individuals experiencing overdose symptoms related to cannabinoid use.

• Opioid Use Disorder Management

  Further broadening its impact, Opiant is working on drug candidates specifically focused on the comprehensive management of opioid use disorders. These therapeutics are designed to support individuals in overcoming addiction while minimizing withdrawal symptoms and cravings, ultimately aiding in sustainable recovery.